| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.874 | 0.003 | 0.874 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | 0.773 0.004 DBMET03510 0.737 0.004 DBMET03511 0.823 0.003 DBMET03512 0.727 0.004 DBMET03513 0.679 0.004 DBMET03514 | ||
| 0.832 | 0.003 | 0.832 | Raf kinase inhibitor | 0.723 0.004 DBMET03510 0.682 0.004 DBMET03511 0.781 0.003 DBMET03512 0.669 0.004 DBMET03513 0.621 0.004 DBMET03514 | ||
| 0.822 | 0.003 | 0.822 | Raf kinase B inhibitor | 0.701 0.003 DBMET03510 0.664 0.003 DBMET03511 0.761 0.003 DBMET03512 0.655 0.003 DBMET03513 0.612 0.004 DBMET03514 | ||
| 0.691 | 0.002 | 0.691 | LIM domain kinase 1 inhibitor | 0.512 0.004 DBMET03510 0.425 0.005 DBMET03511 0.467 0.004 DBMET03512 0.39 0.007 DBMET03513 0.343 0.013 DBMET03514 | ||
| 0.634 | 0.005 | 0.634 | MAP kinase kinase 6 inhibitor | 0.571 0.008 DBMET03510 0.561 0.009 DBMET03511 0.619 0.005 DBMET03512 0.6 0.005 DBMET03513 0.55 0.01 DBMET03514 | ||
| 0.394 | 0.005 | 0.565 | Histone acetyltransferase inhibitor | 0.308 0.012 DBMET03510 0.3 0.014 DBMET03511 0.565 0.003 DBMET03512 0.305 0.013 DBMET03513 0.425 0.005 DBMET03514 | DBMET03512 | |
| 0.393 | 0.004 | 0.393 | Phosphatidylinositol 3-kinase beta inhibitor | 0.195 0.005 DBMET03510 0.163 0.007 DBMET03511 0.187 0.005 DBMET03512 0.117 0.01 DBMET03513 0.099 0.013 DBMET03514 | ||
| 0.392 | 0.013 | 0.392 | MAP kinase kinase 2 inhibitor | 0.378 0.015 DBMET03510 0.278 0.043 DBMET03511 0.37 0.016 DBMET03512 0.261 0.049 DBMET03513 0.285 0.04 DBMET03514 | ||
| 0.366 | 0.004 | 0.366 | Raf kinase C inhibitor | 0.239 0.007 DBMET03510 0.21 0.009 DBMET03511 0.228 0.008 DBMET03512 0.209 0.009 DBMET03513 0.133 0.017 DBMET03514 | ||
| 0.293 | 0.01 | 0.293 | Cyclin-dependent kinase 9 inhibitor | 0.238 0.016 DBMET03510 0.138 0.038 DBMET03511 0.291 0.01 DBMET03512 0.215 0.02 DBMET03513 0.148 0.035 DBMET03514 | ||
| 0.299 | 0.039 | 0.299 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.254 0.059 DBMET03510 0.223 0.075 DBMET03511 0.297 0.04 DBMET03512 0.283 0.045 DBMET03513 0.231 0.071 DBMET03514 | ||
| 0.255 | 0.005 | 0.255 | Phosphatidylinositol 3-kinase delta inhibitor | 0.123 0.015 DBMET03510 0.097 0.02 DBMET03511 0.13 0.014 DBMET03512 0.077 0.027 DBMET03513 0.059 0.038 DBMET03514 | ||
| 0.242 | 0.006 | 0.242 | Phosphatidylinositol kinase inhibitor | 0.135 0.014 DBMET03510 0.099 0.021 DBMET03511 0.134 0.014 DBMET03512 0.092 0.023 DBMET03513 0.072 0.032 DBMET03514 | ||
| 0.257 | 0.027 | 0.257 | Protein kinase (CK1) gamma 1 inhibitor | 0.2 0.042 DBMET03510 0.163 0.059 DBMET03511 0.225 0.035 DBMET03512 0.188 0.047 DBMET03513 0.16 0.061 DBMET03514 | ||
| 0.228 | 0.006 | 0.238 | CDK1/cyclin B1 inhibitor | 0.196 0.009 DBMET03510 0.173 0.012 DBMET03511 0.238 0.005 DBMET03512 0.198 0.008 DBMET03513 0.199 0.008 DBMET03514 | DBMET03512 | |
| 0.264 | 0.05 | 0.264 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.237 0.084 DBMET03510 0.23 0.096 DBMET03511 0.26 0.054 DBMET03512 0.245 0.073 DBMET03513 0.225 0.105 DBMET03514 | ||
| 0.24 | 0.03 | 0.24 | Protein kinase (CK1) gamma 3 inhibitor | 0.205 0.044 DBMET03510 0.178 0.062 DBMET03511 0.227 0.034 DBMET03512 0.2 0.047 DBMET03513 0.183 0.058 DBMET03514 | ||
| 0.255 | 0.054 | 0.255 | EphB2 antagonist | 0.203 0.086 DBMET03510 0.203 0.086 DBMET03511 0.224 0.072 DBMET03512 0.194 0.092 DBMET03513 0.158 0.121 DBMET03514 | ||
| 0.206 | 0.006 | 0.206 | CDK9/cyclin T1 inhibitor | 0.147 0.01 DBMET03510 0.12 0.014 DBMET03511 0.191 0.007 DBMET03512 0.164 0.009 DBMET03513 0.119 0.014 DBMET03514 | ||
| 0.197 | 0.009 | 0.197 | AXL receptor tyrosine kinase inhibitor | 0.151 0.017 DBMET03510 0.123 0.026 DBMET03511 0.186 0.01 DBMET03512 0.172 0.013 DBMET03513 0.125 0.025 DBMET03514 | ||
| 0.222 | 0.036 | 0.222 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | 0.168 0.053 DBMET03510 0.135 0.071 DBMET03511 0.175 0.05 DBMET03512 0.191 0.044 DBMET03513 0.126 0.077 DBMET03514 | ||
| 0.223 | 0.037 | 0.223 | Protein kinase (CK1) gamma inhibitor | 0.168 0.058 DBMET03510 0.139 0.074 DBMET03511 0.179 0.052 DBMET03512 0.147 0.069 DBMET03513 0.125 0.085 DBMET03514 | ||
| 0.225 | 0.04 | 0.283 | Protein kinase C nu inhibitor | 0.283 0.028 DBMET03510 0.143 0.073 DBMET03511 0.206 0.045 DBMET03512 0.153 0.068 DBMET03513 0.142 0.074 DBMET03514 | DBMET03510 | |
| 0.225 | 0.044 | 0.225 | Growth factor agonist | 0.205 0.058 DBMET03510 0.191 0.072 DBMET03511 0.225 0.044 DBMET03512 0.181 0.085 DBMET03513 0.197 0.065 DBMET03514 | ||
| 0.198 | 0.023 | 0.198 | MAP kinase 12 inhibitor | 0.143 0.046 DBMET03510 0.133 0.055 DBMET03511 0.161 0.036 DBMET03512 0.144 0.046 DBMET03513 0.112 0.081 DBMET03514 | ||
| 0.187 | 0.02 | 0.187 | MAP kinase kinase 4 inhibitor | 0.183 0.022 DBMET03510 0.171 0.032 DBMET03511 0.185 0.021 DBMET03512 0.177 0.026 DBMET03513 0.177 0.026 DBMET03514 | ||
| 0.173 | 0.009 | 0.173 | Phosphatidylinositol 3-kinase alpha inhibitor | 0.094 0.018 DBMET03510 0.065 0.027 DBMET03511 0.091 0.018 DBMET03512 0.054 0.034 DBMET03513 0.044 0.043 DBMET03514 | ||
| 0.224 | 0.063 | 0.224 | Death-associated protein kinase 3 inhibitor | 0.169 0.097 DBMET03510 0.164 0.102 DBMET03511 0.201 0.074 DBMET03512 0.175 0.091 DBMET03513 0.151 0.121 DBMET03514 | ||
| 0.339 | 0.181 | 0.482 | Antiinflammatory | 0.42 0.127 DBMET03510 0.439 0.116 DBMET03511 0.304 0.212 DBMET03512 0.288 0.226 DBMET03513 0.482 0.095 DBMET03514 | DBMET03514 | |
| 0.182 | 0.037 | 0.182 | Protein kinase (CK1) gamma 2 inhibitor | 0.135 0.055 DBMET03510 0.112 0.071 DBMET03511 0.142 0.052 DBMET03512 0.116 0.068 DBMET03513 0.102 0.082 DBMET03514 | ||
| 0.185 | 0.045 | 0.185 | CDC-like kinase 1 inhibitor | 0.161 0.062 DBMET03510 0.137 0.08 DBMET03511 0.18 0.048 DBMET03512 0.163 0.06 DBMET03513 0.145 0.074 DBMET03514 | ||
| 0.138 | 0.005 | 0.138 | CDK7/cyclin H inhibitor | 0.096 0.006 DBMET03510 0.081 0.008 DBMET03511 0.136 0.005 DBMET03512 0.126 0.005 DBMET03513 0.082 0.008 DBMET03514 | ||
| 0.136 | 0.004 | 0.136 | Cyclin H inhibitor | 0.123 0.004 DBMET03510 0.115 0.005 DBMET03511 0.135 0.004 DBMET03512 0.124 0.004 DBMET03513 0.115 0.005 DBMET03514 | ||
| 0.155 | 0.023 | 0.155 | CDK3/cyclin E inhibitor | 0.145 0.03 DBMET03510 0.14 0.034 DBMET03511 0.148 0.028 DBMET03512 0.142 0.032 DBMET03513 0.135 0.038 DBMET03514 | ||
| 0.141 | 0.01 | 0.141 | Phosphatidylinositol 3-kinase gamma inhibitor | 0.086 0.018 DBMET03510 0.065 0.028 DBMET03511 0.071 0.024 DBMET03512 0.052 0.042 DBMET03513 | ||
| 0.151 | 0.021 | 0.151 | CC chemokine 6 receptor antagonist | 0.144 0.031 DBMET03510 0.146 0.028 DBMET03511 0.137 0.048 DBMET03512 0.133 0.059 DBMET03513 0.13 0.07 DBMET03514 | ||
| 0.139 | 0.021 | 0.139 | MAP kinase 14 inhibitor | 0.101 0.034 DBMET03510 0.063 0.062 DBMET03512 | ||
| 0.194 | 0.079 | 0.194 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.147 0.115 DBMET03510 0.188 0.083 DBMET03512 0.136 0.128 DBMET03513 | ||
| 0.16 | 0.046 | 0.185 | MAP kinase kinase inhibitor | 0.185 0.034 DBMET03510 0.17 0.041 DBMET03512 0.118 0.076 DBMET03513 0.142 0.056 DBMET03514 | DBMET03510 | |
| 0.172 | 0.064 | 0.172 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.139 0.086 DBMET03510 0.112 0.109 DBMET03511 0.159 0.071 DBMET03512 0.141 0.083 DBMET03513 0.117 0.104 DBMET03514 | ||
| 0.142 | 0.044 | 0.15 | Cyclin-dependent kinase 1 inhibitor | 0.113 0.058 DBMET03510 0.15 0.041 DBMET03512 0.109 0.061 DBMET03513 0.09 0.074 DBMET03514 | DBMET03512 | |
| 0.124 | 0.029 | 0.124 | TIE-2 antagonist | 0.081 0.057 DBMET03512 | ||
| 0.123 | 0.03 | 0.123 | TIE antagonist | 0.081 0.059 DBMET03512 | ||
| 0.151 | 0.059 | 0.159 | MAP3K9 inhibitor | 0.159 0.048 DBMET03510 0.138 0.08 DBMET03511 0.155 0.053 DBMET03512 0.143 0.071 DBMET03513 0.155 0.052 DBMET03514 | DBMET03510 | |
| 0.108 | 0.018 | 0.108 | Transforming growth factor antagonist | 0.073 0.043 DBMET03510 0.076 0.04 DBMET03511 0.095 0.024 DBMET03512 0.073 0.043 DBMET03513 | ||
| 0.186 | 0.102 | 0.221 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.221 0.081 DBMET03510 0.171 0.113 DBMET03512 0.187 0.101 DBMET03514 | DBMET03510 | |
| 0.092 | 0.012 | 0.092 | Transforming growth factor beta 1 antagonist | 0.081 0.014 DBMET03512 | ||
| 0.118 | 0.044 | 0.128 | CDK2/cyclin A inhibitor | 0.116 0.045 DBMET03510 0.082 0.077 DBMET03511 0.128 0.036 DBMET03512 0.103 0.055 DBMET03513 0.103 0.056 DBMET03514 | DBMET03512 | |
| 0.181 | 0.11 | 0.215 | Dyrk kinase inhibitor | 0.215 0.09 DBMET03510 0.164 0.123 DBMET03512 0.174 0.115 DBMET03514 | DBMET03510 | |
| 0.092 | 0.025 | 0.092 | CDK2/cyclin E inhibitor | 0.067 0.036 DBMET03510 0.054 0.049 DBMET03511 0.092 0.026 DBMET03512 0.067 0.036 DBMET03513 0.054 0.049 DBMET03514 | ||
| 0.094 | 0.029 | 0.094 | Vanilloid 1 antagonist | |||
| 0.067 | 0.003 | 0.067 | 2-Acylglycerol O-acyltransferase 2 inhibitor | 0.032 0.004 DBMET03510 0.022 0.004 DBMET03511 0.013 0.005 DBMET03512 0.013 0.005 DBMET03513 | ||
| 0.136 | 0.072 | 0.136 | Nav1.6 sodium channel blocker | 0.135 0.074 DBMET03512 | ||
| 0.066 | 0.005 | 0.066 | LIM domain kinase 2 inhibitor | 0.048 0.006 DBMET03510 0.046 0.007 DBMET03511 0.059 0.005 DBMET03512 0.053 0.005 DBMET03513 0.042 0.008 DBMET03514 | ||
| 0.093 | 0.031 | 0.134 | CDK2/cyclin E2 inhibitor | 0.075 0.043 DBMET03510 0.062 0.06 DBMET03511 0.134 0.02 DBMET03512 0.075 0.043 DBMET03513 0.073 0.045 DBMET03514 | DBMET03512 | |
| 0.092 | 0.034 | 0.132 | Purinergic P2X2 antagonist | 0.089 0.036 DBMET03510 0.07 0.045 DBMET03511 0.132 0.016 DBMET03512 0.065 0.048 DBMET03513 0.099 0.031 DBMET03514 | DBMET03512 | |
| 0.117 | 0.059 | 0.117 | MAP kinase 13 inhibitor | 0.109 0.067 DBMET03512 0.095 0.09 DBMET03513 | ||
| 0.119 | 0.074 | 0.131 | Protein kinase (CK1) delta inhibitor | 0.131 0.065 DBMET03510 0.108 0.084 DBMET03512 | DBMET03510 | |
| 0.077 | 0.035 | 0.086 | CDK1/cyclin B inhibitor | 0.063 0.044 DBMET03510 0.086 0.031 DBMET03512 0.059 0.048 DBMET03513 0.059 0.047 DBMET03514 | DBMET03512 | |
| 0.204 | 0.165 | 0.204 | Angiogenesis inhibitor | |||
| 0.094 | 0.056 | 0.1 | CDK/cyclin complex inhibitor | 0.088 0.061 DBMET03510 0.1 0.052 DBMET03512 | DBMET03512 | |
| 0.062 | 0.028 | 0.067 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.067 0.024 DBMET03510 | DBMET03510 | |
| 0.075 | 0.042 | 0.075 | I kappa B kinase 1 inhibitor | 0.069 0.049 DBMET03510 0.075 0.042 DBMET03512 0.063 0.06 DBMET03514 | ||
| 0.121 | 0.091 | 0.123 | Protein kinase (CK1) inhibitor | 0.123 0.089 DBMET03510 0.106 0.103 DBMET03512 | DBMET03510 | |
| 0.114 | 0.09 | 0.128 | Lck kinase inhibitor | 0.128 0.079 DBMET03512 | DBMET03512 | |
| 0.106 | 0.084 | 0.114 | Cyclin-dependent kinase inhibitor | 0.102 0.088 DBMET03510 0.114 0.078 DBMET03512 | DBMET03512 | |
| 0.124 | 0.105 | 0.124 | Tyrosine kinase inhibitor | |||
| 0.083 | 0.067 | 0.09 | Interleukin 5 antagonist | 0.09 0.055 DBMET03510 0.081 0.07 DBMET03511 0.083 0.066 DBMET03512 0.082 0.069 DBMET03513 0.089 0.056 DBMET03514 | DBMET03510 | |
| 0.055 | 0.041 | 0.055 | Bruton tyrosine kinase inhibitor | |||
| 0.018 | 0.005 | 0.018 | 5 Lipoxygenase activating protein inhibitor | 0.015 0.007 DBMET03510 0.017 0.006 DBMET03511 0.017 0.006 DBMET03512 0.014 0.008 DBMET03513 0.016 0.007 DBMET03514 | ||
| 0.064 | 0.051 | 0.064 | MAP kinase kinase 10 inhibitor | 0.064 0.05 DBMET03512 | ||
| 0.036 | 0.024 | 0.036 | Estradiol 17 beta-dehydrogenase 2 inhibitor | |||
| 0.137 | 0.127 | 0.137 | Clk dual-specificity kinase inhibitor | |||
| 0.085 | 0.078 | 0.105 | MAP kinase kinase 1 inhibitor | 0.105 0.05 DBMET03510 0.102 0.054 DBMET03512 0.087 0.074 DBMET03514 | DBMET03510 | |
| 0.089 | 0.085 | 0.089 | Cyclin-dependent kinase 2 inhibitor | 0.089 0.084 DBMET03512 | ||
| 0.067 | 0.063 | 0.097 | ErbB-4 antagonist | 0.097 0.042 DBMET03512 0.096 0.042 DBMET03513 | DBMET03512 | |
| 0.11 | 0.111 | 0.141 | Cyclooxygenase inhibitor | 0.124 0.094 DBMET03511 0.141 0.078 DBMET03514 | DBMET03514 | |
| 0.054 | 0.058 | 0.059 | p38 MAP kinase inhibitor | 0.059 0.053 DBMET03510 | DBMET03510 | |
| 0.029 | 0.035 | 0.034 | Glutamate (mGluR4) agonist | 0.034 0.023 DBMET03511 0.032 0.028 DBMET03514 | DBMET03511 | |
| 0.077 | 0.088 | 0.082 | MAP kinase 9 inhibitor | 0.082 0.081 DBMET03510 | DBMET03510 | |
| 0.036 | 0.049 | 0.056 | AICAR transformylase inhibitor | 0.045 0.029 DBMET03511 0.045 0.029 DBMET03512 0.056 0.017 DBMET03514 | DBMET03514 | |
| 0.131 | 0.153 | 0.139 | Cyclin-dependent kinase 3 inhibitor | 0.139 0.124 DBMET03512 | DBMET03512 | |
| 0.089 | 0.114 | 0.124 | Protein-tyrosine kinase Lyn inhibitor | 0.124 0.082 DBMET03512 | DBMET03512 | |
| 0.036 | 0.083 | 0.071 | 5 Hydroxytryptamine 6 antagonist | 0.071 0.029 DBMET03512 | DBMET03512 | |
| 0.04 | 0.092 | 0.127 | Lipase inhibitor | 0.127 0.015 DBMET03512 0.112 0.022 DBMET03514 | DBMET03512 | |
| 0.078 | 0.13 | 0.1 | Folate antagonist | 0.093 0.079 DBMET03511 0.09 0.086 DBMET03512 0.1 0.064 DBMET03514 | DBMET03514 | |
| 0.078 | 0.172 | 0.112 | Interleukin 8 antagonist | 0.112 0.073 DBMET03514 | DBMET03514 | |
| 0.072 | 0.167 | 0.107 | Sodium channel (voltage-gated) blocker | 0.107 0.1 DBMET03512 | DBMET03512 | |
| 0.141 | 0.252 | 0.269 | Immunomodulator | 0.269 0.101 DBMET03514 | DBMET03514 | |
| 0.082 | 0.248 | 0.146 | I kappa B kinase epsilon inhibitor | 0.146 0.124 DBMET03513 | DBMET03513 | |
| 0.128 | 0.32 | 0.205 | Toll-Like receptor agonist | 0.205 0.196 DBMET03514 | DBMET03514 | |
| 0.054 | 0.247 | 0.135 | Alpha 2d adrenoreceptor antagonist | 0.135 0.014 DBMET03512 | DBMET03512 | |
| 0.013 | 0.209 | 0.033 | Purinergic P2X3 antagonist | 0.033 0.026 DBMET03510 | DBMET03510 | |
| 0.039 | 0.272 | 0.109 | Cyclooxygenase 1 inhibitor | 0.109 0.091 DBMET03514 | DBMET03514 | |
| 0.073 | 0.511 | 0.634 | Analgesic | 0.634 0.021 DBMET03510 | DBMET03510 | |
| 0.066 | 0.579 | 0.285 | Cyclophilin D inhibitor | 0.285 0.176 DBMET03514 | DBMET03514 | |
| 0.013 | 0.655 | 0.19 | Hypolipemic | 0.19 0.102 DBMET03511 | DBMET03511 | |
| 0.002 | 0.774 | 0.042 | Prostaglandin EP1 antagonist | 0.042 0.008 DBMET03513 | DBMET03513 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |